An advanced three-day course led by international experts in TB diagnostic research.

H3-D director Prof Kelly Chibale, (front centre) with his research team. H3-D's partnership with Novartis will augment support already provided by the South African government's Department of Science & Technology and Technology Innovation Agency to build drug discovery and development capabilities on the African continent.

UCT's Assoc Prof Mark Hatherill is leading a study that will test the safety and immunogenicity of a new TB vaccine, MVA85A, on newborns of HIV-positive mothers.